Antiviral Drugs Market Contributing Large Share
![]() |
Antiviral Drugs Market |
Market Overview:
Antiviral
drugs are therapeutics used to treat infectious diseases caused by viruses such
as influenza, hepatitis, herpes, HIV, and others. These drugs inhibit the
replication of viruses inside host cells. The major classes of antiviral drugs
include reverse transcriptase inhibitors, protease inhibitors, fusion
inhibitors, and neuraminidase inhibitors. These drugs target specific stages of
viral replication cycles to generate antiviral responses. The increasing need
for therapeutics to treat life-threatening viral infections drives the growth
of the antiviral drugs market.
Market key trends:
The increasing prevalence of viral infections have driven demand for more
effective antiviral therapies over the past decade. One key trend gaining
traction in the antiviral drugs market is the development of long-acting
antiviral therapies. Companies are focusing on developing antiviral drugs that
provide longer protection against viral infections compared to conventional
short-acting drugs. For instance, GlaxoSmithKline's cabotegravir is a
long-acting injectable HIV therapy developed to be administered every 2 months
vs daily oral anti-retroviral regimens. Such formulation advances help drive
patient adherence to treatment regimens.
Here is the sample Segment Analysis and Key Takeaways for the given Antiviral
Drugs Market research report:
Segment Analysis
The global Antiviral
Drugs Market Demand is segmented on the basis of drug class,
indication, distribution channel, and region. Based on drug class, the market
is segmented into protease inhibitors, reverse transcriptase inhibitors,
nucleotide polymerase inhibitors, and others. The protease inhibitors segment
dominated the market in 2021 owing to the wide availability of drugs classes
such as ritonavir, lopinavir, and saquinavir used for treating HIV infection.
Key Takeaways
The global antiviral drugs market size is expected to witness high growth,
exhibiting a CAGR of 4.2% over the
forecast period from 2023-2030, due
to increasing prevalence of viral infectious diseases such as HIV, hepatitis, influenza,
and coronavirus. The market was valued at US$ 56,480.7 million in 2021.
Regional analysis - North America dominated the antiviral drugs market in 2021
and is expected to continue its dominance over the forecast period. This is
attributed to the rising prevalence of viral diseases and growing R&D
investments in antiviral drug development in the region. Asia Pacific is
expected to witness the fastest growth over the forecast period owing to
increasing healthcare expenditure and large patient pool suffering from viral
infections in countries like China and India.
Key players - Key players operating in the antiviral drugs market are
GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's
Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company,
Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead
Sciences. Major players are focusing on new product launches, mergers,
acquisitions and collaborations to gain a competitive edge in the market.
Read More:
https://www.dailyprbulletin.com/antiviral-drugs-market-demand-share-and-growth/
Comments
Post a Comment